Biocon Secures ₹4,150 Cr via QIP, Major Funds Subscribe Heavily

HEALTHCAREBIOTECH

Overview

Biocon Ltd. successfully raised ₹4,150 crore through a Qualified Institutional Placement (QIP) on Thursday, January 15. The placement saw significant participation from funds managed by SBI Mutual Fund and ICICI Prudential Mutual Fund, which collectively acquired nearly two-thirds of the shares. Proceeds will primarily fund the acquisition of Mylan's stake in Biocon Biologics and repay debt.

Biocon Secures ₹4,150 Crore via QIP

Biocon Ltd. announced Thursday the successful closure of its Qualified Institutional Placement (QIP) fundraising, securing ₹4,150 crore by issuing over 11.26 crore equity shares. The placement, priced at ₹368.35 per share, represented a slight discount to its previous day's closing price.

Major Institutional Participation Drives Fundraise

Key Indian mutual fund houses, including those managed by SBI Mutual Fund and ICICI Prudential Mutual Fund, were substantial investors, acquiring approximately two-thirds of the shares offered. Mirae Asset Mutual Fund also participated in the placement.

Strategic Use of Proceeds for Biologics Acquisition

The substantial capital infusion is earmarked primarily for the cash consideration required to acquire Mylan Inc.'s stake in Biocon Biologics. A portion will also be utilized to clear debt incurred from acquiring Compulsorily Convertible Debentures (CCDs) in Biocon Biologics, with remaining funds allocated for general corporate needs.

Market Context and Future Outlook

This move is central to Biocon's strategy to consolidate its ownership, aiming to make Biocon Biologics a wholly-owned subsidiary. The company had previously secured approval to raise up to ₹4,500 crore to facilitate this strategic acquisition, which involves a $400 million payment to Mylan. Biocon shares closed 0.4% higher at ₹378.9 on Wednesday. The stock has shown flat performance over the past year, making this capital raise a significant event for its future growth trajectory.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.